Intervention

insulin lispro

ClinicalTrials.gov intervention label

Clinical trials7

Recruiting0

Common conditions7

Lead sponsors shown5

Clinical trials

7 shown

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin InfusionNCT02603510 · 2015-11-01

Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 DiabetesNCT02526810 · 2015-07-01

Normal Versus Dual Wave Insulin Bolus for High-protein FoodNCT02276859 · 2014-10-01

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 DiabetesNCT00960661 · 2009-09-01

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and AdolescentsNCT00115570 · 2005-04-01

Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and AdolescentsNCT00097071 · 2004-10-01

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric PopulationNCT00071448 · 2002-06-01

Common conditions

Diabetes2 Diabetes Mellitus, Type 12 Diabetes Mellitus, Insulin-Dependent1 Diabetes Mellitus, Type 21 Type 1 Diabetes1 Type 1 Diabetes Mellitus1 Type 2 Diabetes Mellitus1

Leading sponsors

Novo Nordisk A/S2 Sanofi2 AstraZeneca1 Medical University of Warsaw1 Third Affiliated Hospital, Sun Yat-Sen University1

Trial status mix

COMPLETED6

UNKNOWN1

Phase mix

PHASE34

PHASE42

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.